corticosterone has been researched along with Fever in 100 studies
Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.
| Excerpt | Relevance | Reference |
|---|---|---|
| "methamphetamine - hyperpyrexia - glucocorticoid - corticosterone." | 7.78 | Involvement of glucocorticoid receptor on hyperpyrexia induced by methamphetamine administration. ( Hishida, S; Kinoshita, H; Minami, T; Nishiguchi, M; Ouchi, H; Tashiro, C; Tatara, T; Yoshida, S, 2012) |
| " Both corticosterone (CORT) and laparotomy cause sensitization, leading to enhanced sickness-induced neuroinflammation or pain (respectively)." | 7.77 | Prior laparotomy or corticosterone potentiates lipopolysaccharide-induced fever and sickness behaviors. ( Barrientos, RM; Eisenach, JC; Fleshner, M; Frank, MG; Hains, LE; Johnson, JD; Loram, LC; Maier, SF; Martin, TJ; Sobesky, J; Strand, KA; Taylor, FR; Watkins, LR; Wieseler, JL; Young, JJ, 2011) |
| " After ad libitum baseline and food restriction to 85% body weights, rats received a sucrose solution once daily for 5 min and 30 s at 10:30 h." | 7.74 | Lesions of the medial prefrontal cortex enhance the early phase of psychogenic fever to unexpected sucrose concentration reductions, promote recovery from negative contrast and enhance spontaneous recovery of sucrose-entrained anticipatory activity. ( Dallman, MF; de Jong, H; Ginsberg, AB; Pecoraro, N, 2008) |
| " To determine whether T cell-dependent immune stimuli activate the PVH in rats, we assessed plasma corticosterone (Cort) levels, fever responses, and c-Fos expression in the PVH in animals treated with intraperitoneal injections of SEB." | 7.71 | Staphylococcal enterotoxin B induces fever, brain c-Fos expression, and serum corticosterone in rats. ( Gaykema, RP; Goehler, LE; Hansen, MK; Kleiner, JL; Maier, SF; Watkins, LR, 2001) |
| "The relation between lipopolysaccharide (LPS)-induced fever and bioavailability of corticosterone (B) was examined in male Wistar rats." | 7.70 | The amount of free corticosterone is increased during lipopolysaccharide-induced fever. ( Cabrera, R; De Kloet, ER; De Nicola, A; Korte, SM; Lentjes, EG; Romijn, F; Schönbaum, E, 2000) |
| " Besides H2S production rate and protein expressions of H2S-related synthases cystathionine β-synthase (CBS), 3-mercaptopyruvate sulfurtransferase (3-MPST) and cystathionine γ-lyase (CSE) in the POA, we also measured deep body temperature (Tb), circulating plasma levels of cytokines and corticosterone in an animal model of systemic inflammation." | 3.85 | Effect of Physical Exercise on the Febrigenic Signaling is Modulated by Preoptic Hydrogen Sulfide Production. ( Antunes-Rodrigues, J; Branco, LG; Coimbra, TM; Fernandez, RA; Francescato, HD; Nogueira, JE; Saia, RS; Soriano, RN, 2017) |
| " The fragmentation protocol was not overly stressful as body weights and water consumption remained unchanged, and plasma corticosterone did not differ between mice subjected to 3 or 9 days of sleep disruption and home cage controls." | 3.79 | Prolonged sleep fragmentation of mice exacerbates febrile responses to lipopolysaccharide. ( Barf, RP; George, A; Opp, MR; Ringgold, KM; Sutton, BC, 2013) |
| "methamphetamine - hyperpyrexia - glucocorticoid - corticosterone." | 3.78 | Involvement of glucocorticoid receptor on hyperpyrexia induced by methamphetamine administration. ( Hishida, S; Kinoshita, H; Minami, T; Nishiguchi, M; Ouchi, H; Tashiro, C; Tatara, T; Yoshida, S, 2012) |
| " Subordinate 129SvEv mice showed body weight gain, hyperphagia, increased adipose fat pads weight and basal plasma corticosterone." | 3.77 | Vulnerability to chronic subordination stress-induced depression-like disorders in adult 129SvEv male mice. ( Bartolomucci, A; Ceresini, G; Dadomo, H; Di Cristo, L; Lori, A; Malinge, I; Palanza, P; Parmigiani, S; Sanghez, V; Sheardown, M, 2011) |
| " The aims of this study were (1) to test the hypothesis that ghrelin administration affects LPS-induced fever; and (2) to assess the putative effects of ghrelin on plasma corticosterone secretion and preoptic region prostaglandin (PG) E(2) levels in euthermic and febrile rats." | 3.77 | Exogenous ghrelin attenuates endotoxin fever in rats. ( Branco, LG; Carnio, EC; Nicoli, LG; Soriano, RN, 2011) |
| " Both corticosterone (CORT) and laparotomy cause sensitization, leading to enhanced sickness-induced neuroinflammation or pain (respectively)." | 3.77 | Prior laparotomy or corticosterone potentiates lipopolysaccharide-induced fever and sickness behaviors. ( Barrientos, RM; Eisenach, JC; Fleshner, M; Frank, MG; Hains, LE; Johnson, JD; Loram, LC; Maier, SF; Martin, TJ; Sobesky, J; Strand, KA; Taylor, FR; Watkins, LR; Wieseler, JL; Young, JJ, 2011) |
| " IBU blocked LPS-induced fever but did not block LPS-induced increases in plasma cytokines and corticosterone in the pregnant dam." | 3.75 | Effects of prenatal immune activation on hippocampal neurogenesis in the rat. ( Ashdown, H; Boksa, P; Cui, K; Luheshi, GN, 2009) |
| " After ad libitum baseline and food restriction to 85% body weights, rats received a sucrose solution once daily for 5 min and 30 s at 10:30 h." | 3.74 | Lesions of the medial prefrontal cortex enhance the early phase of psychogenic fever to unexpected sucrose concentration reductions, promote recovery from negative contrast and enhance spontaneous recovery of sucrose-entrained anticipatory activity. ( Dallman, MF; de Jong, H; Ginsberg, AB; Pecoraro, N, 2008) |
| " However, LPS-induced fever, rises in plasma corticosterone, body weight loss and c-Fos expression in the hypothalamus and caudal brainstem were not altered by i." | 3.74 | Central nervous action of interleukin-1 mediates activation of limbic structures and behavioural depression in response to peripheral administration of bacterial lipopolysaccharide. ( Combe, C; Dantzer, R; Konsman, JP; Luheshi, GN; Poole, S; Veeneman, J, 2008) |
| " rIL-18 did not induce leukocytosis, or changes of circulating concentrations of lipoproteins and corticosterone in mice." | 3.73 | Interleukin-18 does not modulate the acute-phase response. ( Dinarello, CA; Kullberg, BJ; Netea, MG; Stuyt, RJ; van der Meer, JW; Verschueren, I, 2005) |
| " We then measured the corticosterone and fever responses to LPS stimulation during the withdrawal period." | 3.72 | Suppressed fever and hypersensitivity responses in chicks prenatally exposed to opiates. ( Schrott, LM; Sparber, SB, 2004) |
| " To determine whether T cell-dependent immune stimuli activate the PVH in rats, we assessed plasma corticosterone (Cort) levels, fever responses, and c-Fos expression in the PVH in animals treated with intraperitoneal injections of SEB." | 3.71 | Staphylococcal enterotoxin B induces fever, brain c-Fos expression, and serum corticosterone in rats. ( Gaykema, RP; Goehler, LE; Hansen, MK; Kleiner, JL; Maier, SF; Watkins, LR, 2001) |
| "As part of our characterization of the developmental consequences of prenatal cocaine exposure, cocaine was injected into eggs containing viable chicken embryos on embryonic day (E) 18 and the fever response to the endotoxin lipopolysaccharide (LPS) and a delayed-type hypersensitivity response to phytohemagglutinin (PHA) were assessed postnatally." | 3.71 | Embryonic "binge" cocaine exposure alters neural-immune and neural-endocrine interactions in young chickens: involvement of serotonin(2) receptors. ( Schrott, LM; Sparber, SB, 2001) |
| " LPS administration induces a syndrome collectively known as sickness behavior, manifest as altered thermoregulatory processes leading to fever, and increased serum concentrations of neuroendocrine hormones, including corticosterone." | 3.70 | Late embryonic ritanserin exposure fails to alter normal responses to immune system stimulation in young chicks. ( Bodensteiner, KE; Schrott, LM; Sparber, SB; Sweeney, WA, 1999) |
| "The relation between lipopolysaccharide (LPS)-induced fever and bioavailability of corticosterone (B) was examined in male Wistar rats." | 3.70 | The amount of free corticosterone is increased during lipopolysaccharide-induced fever. ( Cabrera, R; De Kloet, ER; De Nicola, A; Korte, SM; Lentjes, EG; Romijn, F; Schönbaum, E, 2000) |
| "Fever is a major component of the host's defense against infection." | 1.38 | Prenatal immune stress in rats dampens fever during adulthood. ( Abdeslam, M; Mouihate, A, 2012) |
| "Autism is a neurodevelopmental disorder characterized by abnormal reciprocal social interactions, communication deficits, and repetitive behaviors with restricted interests." | 1.36 | Low stress reactivity and neuroendocrine factors in the BTBR T+tf/J mouse model of autism. ( Bell, DB; Crawley, JN; Katz, AM; Koenig, JI; Silverman, JL; Turner, SM; Yang, M, 2010) |
| "Neonatal anoxia is an example of early-life threatening experience that might exert long-lasting behavioral disturbance." | 1.36 | Neonatal asphyxia under hyperthermic conditions alters HPA axis function in juvenile rats. ( Caputa, M; Rogalska, J, 2010) |
| "We explored the possibility that REM sleep deprivation may provoke major changes in the immune system by inducing inflammation." | 1.35 | REM sleep deprivation in rats results in inflammation and interleukin-17 elevation. ( Carasso, RL; Kenigsbuch-Sredni, D; Sredni, B; Yehuda, S, 2009) |
| "Fever is the most common manifestation of the innate immune response to invading pathogens." | 1.33 | Early life immune challenge alters innate immune responses to lipopolysaccharide: implications for host defense as adults. ( Ellis, S; Mouihate, A; Pittman, QJ, 2005) |
| "LPS fevers were not induced in these animals." | 1.33 | Transiently enhanced LPS-induced fever following hyperthermic stress in rabbits. ( Nishimaki, M; Riedel, W; Shibata, M; Uno, T; Watanabe, K, 2005) |
| "Since depression is a multifaceted disorder, and a number of symptoms may be present, including circadian rhythm disturbances, we attempted to find the chronobiological abnormalities in CMS rats." | 1.33 | Chronobiological disturbances with hyperthermia and hypercortisolism induced by chronic mild stress in rats. ( Higuchi, S; Morikawa, T; Ohdo, S; To, H; Ushijima, K, 2006) |
| "Corticosterone and endotoxin were first elevated in the circulation at 3 and 18 h after the injection, respectively." | 1.32 | Circulating cytokines and endotoxin are not necessary for the activation of the sickness or corticosterone response produced by peripheral E. coli challenge. ( Biedenkapp, JC; Campisi, J; Fleshner, M; Hansen, MK; Maier, SF; O'Connor, KA; Watkins, LR, 2003) |
| "Pre-treatment with indomethacin reduced the fever and adrenocortical activation induced by gp120 administration, but not its behavioral effects." | 1.31 | Intracerebral HIV-1 glycoprotein 120 produces sickness behavior and pituitary-adrenal activation in rats: role of prostaglandins. ( Barak, O; Ben-Hur, T; Goshen, I; Taylor, AN; Weidenfeld, J; Yirmiya, R, 2002) |
| "Corticosterone treatment also intensified the stress response of cerebellum, including Purkinje cells and Bergmann glia in the molecular layer." | 1.29 | Corticosterone has a permissive effect on expression of heme oxygenase-1 in CA1-CA3 neurons of hippocampus in thermal-stressed rats. ( Eke, BC; Ewing, JF; Maines, MD; Weber, CM, 1995) |
| "In these situations fever is often present." | 1.28 | The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. ( Aarden, LA; Helle, M; van Gool, J; van Vugt, H, 1990) |
| "Fever was continuously recorded and 24 h after induction acute phase reactant (APR) response was measured as indicated by the rise of alpha-macrofetoprotein (alpha M FP, alpha 2 macroglobulin of the rat)." | 1.27 | Fever and acute phase reactants in the rat. ( Deutz, NE; van Gool, J; van Vugt, H, 1988) |
| "A variant of acute febrile neutrophilic dermatosis in which acute myeloid leukemia is present has been reported and seems identical to bullous pyoderma gangrenosum." | 1.27 | Acute febrile neutrophilic dermatosis (Sweet's syndrome) and the related conditions of "bowel bypass" syndrome and bullous pyoderma gangrenosum. ( Callen, JP, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (13.00) | 18.7374 |
| 1990's | 21 (21.00) | 18.2507 |
| 2000's | 40 (40.00) | 29.6817 |
| 2010's | 25 (25.00) | 24.3611 |
| 2020's | 1 (1.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista, TH | 1 |
| Ribeiro, ACAF | 1 |
| Kalil, B | 1 |
| Giusti-Paiva, A | 1 |
| Vilela, FC | 1 |
| Parent, C | 1 |
| Nguyen, HB | 1 |
| Wen, X | 1 |
| Diorio, J | 1 |
| Meaney, MJ | 1 |
| Zhang, TY | 1 |
| Matsuwaki, T | 1 |
| Shionoya, K | 1 |
| Ihnatko, R | 1 |
| Eskilsson, A | 1 |
| Kakuta, S | 1 |
| Dufour, S | 1 |
| Schwaninger, M | 1 |
| Waisman, A | 1 |
| Müller, W | 1 |
| Pinteaux, E | 1 |
| Engblom, D | 1 |
| Blomqvist, A | 1 |
| Hargis, K | 1 |
| Buechel, HM | 1 |
| Popovic, J | 1 |
| Blalock, EM | 1 |
| Ringgold, KM | 1 |
| Barf, RP | 1 |
| George, A | 1 |
| Sutton, BC | 1 |
| Opp, MR | 1 |
| Soriano, RN | 3 |
| Ravanelli, MI | 1 |
| Batalhao, ME | 1 |
| Carnio, EC | 2 |
| Branco, LG | 3 |
| MacDonald, L | 1 |
| Hazi, A | 1 |
| Paolini, AG | 1 |
| Kent, S | 1 |
| Gonzales, C | 1 |
| Zaleska, MM | 1 |
| Riddell, DR | 1 |
| Atchison, KP | 1 |
| Robshaw, A | 1 |
| Zhou, H | 1 |
| Sukoff Rizzo, SJ | 1 |
| Barbier, L | 1 |
| Canini, F | 1 |
| Giroud, C | 1 |
| Beaup, C | 1 |
| Foquin, A | 1 |
| Maury, R | 1 |
| Denis, J | 1 |
| Peinnequin, A | 1 |
| Dorandeu, F | 1 |
| Watanabe, S | 1 |
| Miyamoto, T | 1 |
| Funakami, Y | 1 |
| Kawashita, E | 1 |
| Nomura, A | 1 |
| Sugimoto, N | 1 |
| Saeki, H | 1 |
| Tsubota, M | 1 |
| Ichida, S | 1 |
| Kawabata, A | 1 |
| Nogueira, JE | 1 |
| Fernandez, RA | 1 |
| Francescato, HD | 1 |
| Saia, RS | 1 |
| Coimbra, TM | 1 |
| Antunes-Rodrigues, J | 1 |
| Painsipp, E | 2 |
| Herzog, H | 2 |
| Holzer, P | 2 |
| Amico, JA | 1 |
| Miedlar, JA | 1 |
| Cai, HM | 1 |
| Vollmer, RR | 1 |
| Konsman, JP | 1 |
| Veeneman, J | 1 |
| Combe, C | 1 |
| Poole, S | 2 |
| Luheshi, GN | 3 |
| Dantzer, R | 2 |
| Mitsukawa, K | 1 |
| Lu, X | 1 |
| Bartfai, T | 3 |
| Johnson, BN | 1 |
| Yamamoto, BK | 3 |
| Yehuda, S | 1 |
| Sredni, B | 1 |
| Carasso, RL | 1 |
| Kenigsbuch-Sredni, D | 1 |
| Cui, K | 1 |
| Ashdown, H | 1 |
| Boksa, P | 1 |
| Doyle, JR | 1 |
| Rogalska, J | 1 |
| Caputa, M | 1 |
| Silverman, JL | 1 |
| Yang, M | 1 |
| Turner, SM | 1 |
| Katz, AM | 1 |
| Bell, DB | 1 |
| Koenig, JI | 1 |
| Crawley, JN | 1 |
| Dadomo, H | 1 |
| Sanghez, V | 1 |
| Di Cristo, L | 1 |
| Lori, A | 1 |
| Ceresini, G | 1 |
| Malinge, I | 1 |
| Parmigiani, S | 1 |
| Palanza, P | 1 |
| Sheardown, M | 1 |
| Bartolomucci, A | 1 |
| Nicoli, LG | 1 |
| Alexander, BN | 1 |
| Fewell, JE | 2 |
| Yee, N | 1 |
| Plassmann, K | 1 |
| Fuchs, E | 1 |
| Kiselycznyk, C | 1 |
| Svenningsson, P | 1 |
| Delpire, E | 1 |
| Holmes, A | 1 |
| Sartori, SB | 1 |
| Whittle, N | 1 |
| Hetzenauer, A | 1 |
| Singewald, N | 2 |
| Bravo, JA | 1 |
| Forsythe, P | 1 |
| Chew, MV | 1 |
| Escaravage, E | 1 |
| Savignac, HM | 1 |
| Dinan, TG | 1 |
| Bienenstock, J | 1 |
| Cryan, JF | 2 |
| Hains, LE | 1 |
| Loram, LC | 1 |
| Taylor, FR | 1 |
| Strand, KA | 1 |
| Wieseler, JL | 1 |
| Barrientos, RM | 1 |
| Young, JJ | 1 |
| Frank, MG | 1 |
| Sobesky, J | 1 |
| Martin, TJ | 1 |
| Eisenach, JC | 1 |
| Maier, SF | 3 |
| Johnson, JD | 1 |
| Fleshner, M | 2 |
| Watkins, LR | 4 |
| Mete, F | 1 |
| Kilic, E | 1 |
| Somay, A | 1 |
| Yilmaz, B | 1 |
| Mouihate, A | 4 |
| Abdeslam, M | 1 |
| Yoshida, S | 1 |
| Kinoshita, H | 1 |
| Tatara, T | 1 |
| Tashiro, C | 1 |
| Nishiguchi, M | 1 |
| Ouchi, H | 1 |
| Minami, T | 1 |
| Hishida, S | 1 |
| Barak, O | 1 |
| Weidenfeld, J | 1 |
| Goshen, I | 1 |
| Ben-Hur, T | 1 |
| Taylor, AN | 4 |
| Yirmiya, R | 3 |
| Campisi, J | 1 |
| Hansen, MK | 2 |
| O'Connor, KA | 2 |
| Biedenkapp, JC | 1 |
| HERMANS, EH | 1 |
| GERMERAAD, WF | 1 |
| Matuszewich, L | 1 |
| Veening, JG | 1 |
| Bouwknecht, JA | 1 |
| Joosten, HJ | 1 |
| Dederen, PJ | 1 |
| Zethof, TJ | 2 |
| Groenink, L | 4 |
| van der Gugten, J | 4 |
| Olivier, B | 4 |
| Schrott, LM | 3 |
| Sparber, SB | 3 |
| Steiner, AA | 1 |
| Dogan, MD | 1 |
| Ivanov, AI | 2 |
| Patel, S | 1 |
| Rudaya, AY | 1 |
| Jennings, DH | 1 |
| Orchinik, M | 1 |
| Pace, TW | 1 |
| Romanovsky, AA | 2 |
| Tio, DL | 3 |
| Romeo, HE | 1 |
| Koshibu, K | 2 |
| Ahrens, ET | 1 |
| Levitt, P | 2 |
| Ellis, GS | 1 |
| Carlson, DE | 1 |
| Hester, L | 1 |
| He, JR | 1 |
| Bagby, GJ | 1 |
| Singh, IS | 1 |
| Hasday, JD | 1 |
| Deak, T | 3 |
| Bellamy, C | 1 |
| Bordner, KA | 1 |
| Stuyt, RJ | 1 |
| Netea, MG | 1 |
| Verschueren, I | 1 |
| Dinarello, CA | 2 |
| Kullberg, BJ | 1 |
| van der Meer, JW | 1 |
| Owen-Ashley, NT | 1 |
| Turner, M | 1 |
| Hahn, TP | 1 |
| Wingfield, JC | 1 |
| Ellis, S | 3 |
| Pittman, QJ | 3 |
| Shibata, M | 1 |
| Uno, T | 1 |
| Riedel, W | 1 |
| Nishimaki, M | 1 |
| Watanabe, K | 1 |
| Gray, DA | 1 |
| Maloney, SK | 1 |
| Kamerman, PR | 1 |
| Harré, EM | 1 |
| Walker, FR | 1 |
| Hodyl, NA | 1 |
| Krivanek, KM | 1 |
| Hodgson, DM | 1 |
| Whyte, DG | 1 |
| Johnson, AK | 1 |
| Ushijima, K | 1 |
| Morikawa, T | 1 |
| To, H | 1 |
| Higuchi, S | 1 |
| Ohdo, S | 1 |
| Jacobson, LH | 1 |
| Bettler, B | 1 |
| Kaupmann, K | 1 |
| Barnum, CJ | 2 |
| Blandino, P | 2 |
| Wultsch, T | 1 |
| Edelsbrunner, ME | 1 |
| Tasan, RO | 1 |
| Pecoraro, N | 1 |
| de Jong, H | 1 |
| Ginsberg, AB | 1 |
| Dallman, MF | 1 |
| Abdullin, GZ | 1 |
| Medvedeva, GI | 1 |
| Nilova, LP | 1 |
| Maines, MD | 1 |
| Eke, BC | 1 |
| Weber, CM | 1 |
| Ewing, JF | 1 |
| McClellan, JL | 3 |
| Klir, JJ | 2 |
| Morrow, LE | 3 |
| Kluger, MJ | 4 |
| Schöbitz, B | 1 |
| Holsboer, F | 1 |
| Sutanto, W | 1 |
| Gross, G | 1 |
| Schönbaum, E | 2 |
| de Kloet, ER | 2 |
| Strijbos, PJ | 1 |
| Horan, MA | 1 |
| Carey, F | 1 |
| Rothwell, NJ | 2 |
| Conn, CA | 2 |
| Compaan, J | 1 |
| Zethof, T | 1 |
| van der Heyden, J | 1 |
| van der Heyden, JA | 1 |
| Chai, Z | 2 |
| Alheim, K | 2 |
| Lundkvist, J | 1 |
| Gatti, S | 1 |
| Fantuzzi, G | 1 |
| Hasanvan, H | 1 |
| Malinowsky, D | 1 |
| Di Santo, E | 1 |
| Ghezzi, P | 1 |
| Rudolph, K | 1 |
| Soszynski, D | 1 |
| Leon, LR | 1 |
| Kozak, W | 1 |
| Wallen, ES | 1 |
| Moseley, PL | 1 |
| Smith, FG | 1 |
| Abu-Amarah, I | 1 |
| Horai, R | 1 |
| Asano, M | 1 |
| Sudo, K | 1 |
| Kanuka, H | 1 |
| Suzuki, M | 1 |
| Nishihara, M | 1 |
| Takahashi, M | 1 |
| Iwakura, Y | 1 |
| Huang, QH | 1 |
| Hruby, VJ | 1 |
| Tatro, JB | 1 |
| Lenczowski, MJ | 2 |
| Bluthé, RM | 1 |
| Roth, J | 1 |
| Rees, GS | 1 |
| Rushforth, DA | 1 |
| van Dam, AM | 2 |
| Tilders, FJ | 3 |
| Sweeney, WA | 1 |
| Bodensteiner, KE | 1 |
| Cabrera, R | 1 |
| Korte, SM | 1 |
| Lentjes, EG | 1 |
| Romijn, F | 1 |
| De Nicola, A | 1 |
| Nava, F | 1 |
| Carta, G | 1 |
| Kulchitsky, VA | 1 |
| Homer, LD | 1 |
| Goehler, LE | 1 |
| Gaykema, RP | 1 |
| Kleiner, JL | 1 |
| Pattij, T | 1 |
| Hijzen, TH | 1 |
| Oosting, RS | 1 |
| Maes, RA | 1 |
| Hen, R | 1 |
| Wolfenson, D | 1 |
| Bachrach, D | 1 |
| Maman, M | 1 |
| Graber, Y | 1 |
| Rozenboim, I | 1 |
| Vlădescu, C | 2 |
| Roszkowski, AP | 1 |
| Schuler, ME | 1 |
| Coelho, MM | 1 |
| Souza, GE | 1 |
| Pelá, IR | 1 |
| Derijk, R | 1 |
| Van Rooijen, N | 1 |
| Besedovsky, HO | 1 |
| Del Rey, A | 1 |
| Berkenbosch, F | 1 |
| van Gool, J | 2 |
| van Vugt, H | 2 |
| Helle, M | 1 |
| Aarden, LA | 1 |
| Deutz, NE | 1 |
| Daynes, RA | 1 |
| Robertson, BA | 1 |
| Cho, BH | 1 |
| Burnham, DK | 1 |
| Newton, R | 1 |
| Callen, JP | 1 |
| Groza, P | 1 |
| Bordeianu, A | 1 |
| Boerescu, J | 1 |
| Dumitrescu-Papahagi, E | 1 |
| Daneliuc, E | 1 |
| Stoenescu, L | 1 |
| Nicolescu, E | 1 |
| Wewalka, F | 1 |
| Cooper, JE | 1 |
| Byrd, BF | 1 |
| Daniel, RA | 1 |
| Vasudeo, P | 1 |
| Vigas, M | 1 |
| Németh, S | 1 |
| Collins, KJ | 1 |
| Few, JD | 1 |
| Forward, TJ | 1 |
| Giec, LA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of One Month of Daily Consumption of Mineral Water Rich in Magnesium on Perceived Stress in Healthy Consumers.[NCT02719925] | 256 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression[NCT02035878] | Phase 2 | 75 participants (Actual) | Interventional | 2012-08-31 | Active, not recruiting | ||
| Randomized Controlled Experimental Trial Designed to Test the Effects of Probiotics on Mood[NCT03539263] | 39 participants (Actual) | Interventional | 2016-12-20 | Completed | |||
| Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects[NCT05808101] | 120 participants (Anticipated) | Observational | 2022-01-27 | Recruiting | |||
| Understanding the Neurocognitive Effects of Fecal Microbiota Transplantation in Major Depressive Disorder Patients With and Without Irritable Bowel Syndrome[NCT05174273] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2022-04-06 | Recruiting | ||
| The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972] | Phase 2 | 16 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants) | ||
| "Proof-of-Concept Stress & Anxiety Dampening Effects of Lpc-37"[NCT03494725] | 120 participants (Actual) | Interventional | 2018-04-10 | Completed | |||
| The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients[NCT03403907] | 45 participants (Actual) | Interventional | 2014-10-01 | Completed | |||
| A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder[NCT03279224] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2018-01-01 | Active, not recruiting | ||
| Role of the Gut Microbiome in Complex Regional Pain Syndrome[NCT03612193] | 140 participants (Anticipated) | Observational | 2018-12-19 | Recruiting | |||
| Beta-Blockers and Inflammatory Responses to Acute Psychosocial Stress[NCT02972554] | Phase 4 | 92 participants (Actual) | Interventional | 2016-01-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Efficacy of the intake of Lpc-37 on reduction of the increase of the diastolic BP in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 3 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | mmHg (Mean) | |
|---|---|---|
| Pre-TSST -3min | Post-TSST +1min | |
| Lpc-37 | 79.13 | 90.38 |
| Placebo | 78.41 | 88.36 |
"Efficacy of the intake of Lpc-37 on the increase of mood scale scores over the course of the treatment~Measured with a daily online diary. Mood was rated by participants on an 11-point scale (0-10; very bad to very well) and monitored through the washout phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Higher scores indicate a better mood. Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one average value for each week and participant. Values reflect summary measures for mood ratings on a scale from 0 to 10 for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 7.31 | 7.53 | 7.66 | 7.77 | 7.73 | 7.90 | 7.77 |
| Placebo | 7.27 | 7.49 | 7.46 | 7.53 | 7.50 | 7.40 | 7.55 |
"Efficacy of the intake of Lpc-37 on the increase of perceived health status scores over the course of the treatment.~Measured with a daily online diary. Health status was rated by participants on an 11-point scale (0-10; not at all to very) and monitored through the wash-out phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Higher scores indicate a high perceived health.Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Values reflect summary measures for perceived health status on a scale from 0 to 10 for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 7.80 | 7.89 | 7.88 | 7.91 | 8.05 | 8.11 | 7.91 |
| Placebo | 7.86 | 7.92 | 7.92 | 8.01 | 7.92 | 7.73 | 7.75 |
"Efficacy of the intake of Lpc-37 on the increase of perceived productivity scores over the course of the treatment~Measured with a daily online diary. Productivity was rated by participants on an 11-point scale (0-10; not at all to very) and monitored through the wash-out phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Higher scores indicate a higher perceived productivity. Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group.Time is coded as a continuous variable with one value for each day and participant. The values reflect summary measures for perceived productivity on a scale from 0 to 10 for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 6.98 | 7.34 | 7.53 | 7.48 | 7.59 | 7.57 | 7.50 |
| Placebo | 7.15 | 7.29 | 7.30 | 7.34 | 7.43 | 7.31 | 7.32 |
"Efficacy of the intake of Lpc-37 on the decrease of reported number of sleep disruptions over the course of the treatment measured with a daily online diary (mean of week summary).~Sleep disruptions were monitored through the wash-out phase (Week 1 and 2) and the subsequent treatment phase (Weeks 3-7). In the count version, the value can be 0 or a natural number for each day and each participant. Efficacy is defined as a decrease, or (in case of a general increase) reduced increase for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Values reflect summary measures for sleep disruptions (count) for the summed counts per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | sleep disruptions per participant & week (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 7.30 | 5.50 | 4.89 | 5.43 | 3.52 | 3.80 | 4.66 |
| Placebo | 6.09 | 5.49 | 5.11 | 4.30 | 3.53 | 4.02 | 5.83 |
"Efficacy of the intake of Lpc-37 on the decrease of sleep disruptions over the course of the treatment measured with a daily online diary (Proportion (yes/total)).~Sleep disruptions were monitored through the wash-out phase and the subsequent treatment phase for each week. In the binary version, the value is either Yes or No for each day and each participant.~Efficacy is defined as a decrease, or (in case of a general increase) reduced increase for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant.~The proportion of participants with at least one sleep disruption by treatment group is given, treatment commenced after week 2. Data listed here reflect the proportion of participants who answered Yes (e.g. 0,477 * 44 = 20.99 participants answered with Yes in week 1 in the Lpc-37 group)." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | Proportion of participants (yes/total) (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 0.477 | 0.435 | 0.354 | 0.367 | 0.306 | 0.279 | 0.290 |
| Placebo | 0.465 | 0.426 | 0.418 | 0.310 | 0.292 | 0.331 | 0.389 |
Efficacy of the intake of Lpc-37 on reduction of the increase of salivary Alpha-Amylase (sAA) in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 1 minute before the TSST and 1, 10, 20, 30 and 45 minutes after the TSST after 5 weeks of study product intake
| Intervention | U/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| Pre-TSST -2min | Post-TSST +1min | Post-TSST +10min | Post-TSST +20min | Post-TSST +30min | Post-TSST +45min | |
| Lpc-37 | 154.04 | 246.29 | 146.53 | 130.11 | 125.19 | 141.13 |
| Placebo | 161.67 | 270.55 | 158.85 | 141.49 | 138.48 | 148.15 |
Efficacy of the intake of Lpc-37 on reduction of the increase of salivary cortisol in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 1 minute before the TSST and 1, 10, 20, 30 and 45 minutes after the TSST after 5 weeks of study product intake
| Intervention | nmol/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Pre-TSST -2min | Post-TSST +1min | Post-TSST +10min | Post-TSST +20min | Post-TSST +30min | Post-TSST +45min | |
| Lpc-37 | 4.79 | 6.96 | 9.48 | 9.89 | 8.04 | 6.21 |
| Placebo | 4.82 | 6.85 | 8.97 | 9.21 | 7.71 | 6.16 |
"Efficacy of the intake of Lpc-37 on the increase of sleep duration over the course of the treatment.~Sleep duration was monitored through the wash-out phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Summary measures for Sleep duration for the averaged ratings per participant and week" (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | min (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 447.27 | 444.01 | 449.45 | 450.62 | 454.50 | 450.88 | 445.60 |
| Placebo | 447.45 | 448.13 | 456.90 | 459.81 | 457.26 | 450.16 | 459.66 |
"Efficacy of the intake of Lpc-37 on the increase of sleep related recovery scores over the course of the treatment.~Measured with a daily online diary. Sleep related recovery was rated by participants on an 11-point scale (0-10; not at all to very) and monitored throughout the wash-out phase (Week 1 and 2) and the subsequent treatment phase (weeks 3-7). High scores indicate a high recovery.~Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Summary measures for sleep related recovery for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 6.71 | 7.07 | 7.32 | 7.30 | 7.36 | 7.42 | 7.31 |
| Placebo | 6.91 | 7.15 | 7.27 | 7.29 | 7.36 | 7.10 | 7.28 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of STAI-State scores in response to the TSST compared to placebo.~Measured with the german version of the State-Trait-Anxiety Inventory, scale anxiety as a temporary emotional state (STAI-X1). Answers are given on a four-point rating scale ranging from 1=not at all to 4=very true. The score range is 20-80; Higher scores indicate more anxiety." (NCT03494725)
Timeframe: 10 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | |
|---|---|---|
| Pre-TSST -10min | Post-TSST +1min | |
| Lpc-37 | 36.09 | 42.38 |
| Placebo | 36.83 | 43.60 |
Efficacy of the intake of Lpc-37 on reduction of the increase of the systolic BP in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 3 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | mmHg (Mean) | |
|---|---|---|
| Pre-TSST -3min | Post-TSST +1min | |
| Lpc-37 | 115.11 | 127.47 |
| Placebo | 114.33 | 129.19 |
Efficacy was defined as a lower increase in HR in response to the TSST following intervention with Lpc-37, compared to placebo. (NCT03494725)
Timeframe: Continuous measurement starting 20 minutes before and ending 20 minutes after the TSST after 5 weeks of product intake. Mean values were calculated per group at seven-time windows before, during and after the TSST
| Intervention | bpm (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Pre-TSST -20min | Pre-TSST -10min | Pre-TSST -3min | during TSST (Interview) | during TSST (Arithmetic) | Post-TSST +10min | Post-TSST +20min | |
| Lpc-37 | 74.84 | 88.15 | 97.34 | 107.56 | 102.77 | 93.32 | 75.88 |
| Placebo | 74.34 | 86.69 | 97.62 | 105.66 | 100.81 | 90.81 | 74.97 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS anxiety scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater anxiety." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 6.80 | 20.85 | 10.68 |
| Placebo | 8.50 | 22.47 | 11.74 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS exhaustion scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater exhaustion." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 21.18 | 19.20 | 22.12 |
| Placebo | 19.79 | 21.30 | 25.68 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS insecurity scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater insecurity." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 14.47 | 45.08 | 23.92 |
| Placebo | 17.19 | 52.19 | 23.69 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS Stress perception scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating higher perceived stress." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 19.89 | 47.71 | 31.72 |
| Placebo | 18.52 | 51.51 | 32.85 |
"Efficacy of the intake of Lpc-37 on the reduction of Beck Anxiety Inventory (BAI) scores compared to placebo.~Measured with the german version of the Beck Anxiety Inventory as a self-rating scale designed to measure anxiety. It comprises 21 sentences describing feelings that can occur when being anxious. These sentences are rated on a four-point rating scale ranging from 0=not at all to 3=severely, considering the last 7 days. The score range is 0-63; Higher scores indicate higher anxiety." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 5.51 | 4.75 |
| Placebo | 5.85 | 6.33 |
"Efficacy of the intake of Lpc-37 on the reduction of Depression Anxiety Stress Scale (DASS) anxiety scores compared to placebo.~Measured with the german version of the DASS as a 42-item self report instrument designed to measure negative emotional states of depression, anxiety and stress during the past week. The DASS includes three scales (depression, anxiety and stress) of which each scale includes 14 items that are divided into subscales of 2-5 items of similar content.~Items are answered on a four point rating scale ranging from 0 = not at all to 3 = very much. Scores of each scale are calculated by summing the scores for the relevant items.~The anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect. The items are 2, 4, 7, 9, 15, 19, 20, 23, 25, 28, 30, 36, 40, 41 and individual scores can range from 0 to 42 with higher scores indicating greater severity of the symptoms." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 2.60 | 2.44 |
| Placebo | 3.07 | 3.45 |
"Efficacy of the intake of Lpc-37 on the reduction of Depression Anxiety Stress Scale (DASS) depression scores compared to placebo.~Measured with the german version of the DASS as a 42-item self report instrument designed to measure negative emotional states of depression, anxiety and stress during the past week. The DASS includes three scales (depression, anxiety and stress) of which each scale includes 14 items that are divided into subscales of 2-5 items of similar content.~Items are answered on a four point rating scale ranging from 0 = not at all to 3 = very much. Scores of each scale are calculated by summing the scores for the relevant items.~The Depression scale assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest/involvement, anhedonia, and inertia. The items are 3, 5, 10, 13, 16, 17, 21, 24, 26, 31, 34, 37, 38, 42 and individual scores can range from 0 to 42 with higher scores indicating greater severity of the symptoms." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 4.60 | 4.15 |
| Placebo | 5.21 | 5.10 |
"Efficacy of the intake of Lpc-37 on the reduction of Depression Anxiety Stress Scale (DASS) stress scores compared to placebo.~Measured with the german version of the DASS as a 42-item self report instrument designed to measure negative emotional states of depression, anxiety and stress during the past week. The DASS includes three scales (depression, anxiety and stress) of which each scale includes 14 items that are divided into subscales of 2-5 items of similar content.~Items are answered on a four point rating scale ranging from 0 = not at all to 3 = very much. Scores of each scale are calculated by summing the scores for the relevant items.~The stress scale (items) is sensitive to levels of chronic non-specific arousal.The stress scale items are 1, 6, 8, 11, 12, 14, 18, 22, 27, 29, 32, 33, 35, 39 and individual scores can range from 0 to 42 with higher scores indicating greater severity of the symptoms." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 9.76 | 8.91 |
| Placebo | 9.41 | 10.09 |
Efficacy of the intake of Lpc-37 on the reduction of diastolic BP. (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 71.89 | 73.18 |
| Placebo | 71.68 | 74.62 |
"Efficacy of the intake of Lpc-37 on the reduction of Perceived Stress Scale (PSS) scores compared to placebo.~Measured with the german version of the PSS as a psychological instrument for measuring stress perception. It assesses how unpredictable, uncontrollable and overloaded participants perceived their lives to have been within the last month. The PSS comprises 14 items that are answered on a five-point rating scale ranging from 0 = never to 4 = very often. Individual scores on the PSS can range from 0 to 56 with higher scores indicating higher perceived stress." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 21.89 | 20.49 |
| Placebo | 20.72 | 21.56 |
"Efficacy of the intake of Lpc-37 on the reduction of State-Trait-Anxiety-Inventory (STAI)-state scores compared to placebo.~Measured with the german version of the State-Trait-Anxiety Inventory, scale anxiety as a temporary emotional state (STAI-X1). Answers are given on a four-point rating scale ranging from 1=not at all to 4=very true. The score range is 20-80; Higher scores indicate more anxiety." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 33.65 | 35.18 |
| Placebo | 34.33 | 35.33 |
Efficacy of the intake of Lpc-37 on the reduction of systolic blood pressure (BP). (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 119.60 | 121.87 |
| Placebo | 119.66 | 122.86 |
"Efficacy of the intake of Lpc-37 on the reduction of VAS anxiety scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater anxiety." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 7.29 | 9.26 |
| Placebo | 7.58 | 7.85 |
"Efficacy of the intake of Lpc-37 on the reduction of VAS exhaustion scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater exhaustion." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 29.56 | 24.66 |
| Placebo | 23.19 | 18.45 |
"Efficacy of the intake of Lpc-37 on the reduction of VAS insecurity scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater insecurity." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 13.58 | 16.44 |
| Placebo | 15.91 | 17.30 |
"Efficacy of the intake of Lpc-37 on the reduction of Visual Analog Scale (VAS) stress perception scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating higher perceived stress." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 19.11 | 23.32 |
| Placebo | 19.34 | 20.67 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of cortisol at 8 pm values to the respective mean before and after 5 weeks of treatment~Efficacy for the CAR variable cortisol at 8 pm is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 4 | 20 | 29 | 3 | 28 | 22 |
| Placebo | 6 | 23 | 26 | 7 | 18 | 30 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of Cortisol Awakening Response (CAR) area under the curve with respect to the ground (AUCg) values to the respective mean before and after 5 weeks of treatment.~The CAR is summarized in the variables AUCg, AUCi, mean increase and peak value. These cortisol indices are frequently used to describe hypothalamic-pituitary-adrenal axis activity and represent information either of the total cortisol production or of the change in cortisol levels. AUCg is the total area under the curve of all measurements (i.e., the intensity or magnitude of the response).~Efficacy for the CAR variables AUCg is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake)
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 6 | 36 | 11 | 11 | 28 | 14 |
| Placebo | 12 | 30 | 13 | 7 | 35 | 13 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of Cortisol at Awakening values to the respective mean before and after 5 weeks of treatment~Efficacy for the CAR variable cortisol at awakening is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake)
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 14 | 31 | 8 | 19 | 26 | 8 |
| Placebo | 16 | 26 | 13 | 12 | 34 | 9 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of CAR area under the curve with respect to the increase (AUCi) values to the respective mean before and after the treatment.~The CAR is summarized in the variables AUCg, AUCi, mean increase and peak value. These cortisol indices are frequently used to describe hypothalamic-pituitary-adrenal axis activity and represent information either of the total cortisol production or of the change in cortisol levels. AUCi is calculated with reference to the baseline measurement and it ignores the distance from zero for all measurements and emphasizes the changes over time. Efficacy for the CAR variables AUCi is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake)
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 16 | 34 | 3 | 15 | 34 | 4 |
| Placebo | 22 | 28 | 5 | 15 | 36 | 4 |
Measured in blood plasma using enzyme-linked immunosorbent assay. Log-transformed prior to analysis to correct for skew in data. Four different change scores were calculated: first, change at post-drug from pre-drug baseline; second, the change at 30-min post-stressor from post-drug baseline; third, change at 60-min post-stressor from post-drug baseline; and fourth, change at 90-min post-stressor from post-drug baseline. (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 30-min post-stressor; 60-min post-stressor; 90-min post-stressor
| Intervention | log(picograms/mL) (Mean) | |||
|---|---|---|---|---|
| Post-drug from pre-drug baseline | 30-min post-stress from post-drug baseline | 60-min post-stress from post-drug baseline | 90-min post-stress from post-drug baseline | |
| Placebo | .16 | .24 | .19 | .46 |
| Propanolol Hydrochloride | .05 | .31 | .32 | .48 |
"Self-report measure of affect (emotion) state using the Positive & Negative Affect Schedule Negative Affect (PANAS). Answered on a Likert scale from 0 (not at all) - 6 (very much). Mean score range is from 0-6. Higher numbers indicate more negative, high arousal emotions; low numbers indicate less negative, high arousal emotions. Three change scores were calculated from the four different rating measurement time points: a change in negative, high arousal emotions at the post-drug baseline from the pre-drug baseline; a change in emotions right before the Trier Social Stress Task (TSST) from the post-drug baseline; and a change in emotions during the TSST from the post-drug baseline." (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 2-min before the stressor; 1-min post-stressor
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Post-drug from pre-drug baseline | TSST-prep from post-drug baseline | TSST stressor from post-drug baseline | |
| Placebo | -.13 | .37 | .76 |
| Propanolol Hydrochloride | -.10 | .18 | .61 |
Mean level pre-ejection period (PEP; centered at zero) derived from impedance cardiography and electrocardiogram. Four different change scores were calculated: first, the change in average PEP from the 5-min pre-drug baseline to the 5-min post-drug baselines; second, the change in average PEP that occurred during the 2-min anticipatory stress speech preparation phase of the Trier Social Stress Test (TSST) from the post-drug baseline; third, the change in average PEP that occurred across the 15-min of the TSST (speech + math tasks) from the post-drug baseline; fourth and finally, the change in average PEP that occurred across 7-min in a post-stressor recovery period as compared to the post-drug baseline. (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 2-min before the stressor; 15-min during stressor, 7-min recovery post-stressor
| Intervention | milliseconds (Mean) | |||
|---|---|---|---|---|
| Post-drug from pre-drug baseline | TSST-prep from post-drug baseline | TSST from post-drug baseline | Post-stress recovery from post-drug baseline | |
| Placebo | .86 | -10.92 | -10.69 | -1.19 |
| Propanolol Hydrochloride | 7.14 | -5.33 | -.80 | .21 |
Mean level respiratory sinus arrhythmia (RSA) derived from electrocardiogram; measure of heart rate variability assessed as the ratio of low-to-high frequencies in the respiratory-cardiac power spectrum. Four different change scores were calculated: first, the change in average RSA from the 5-min pre-drug baseline to the 5-min post-drug baselines; second, the change in average RSA that occurred during the 2-min anticipatory stress speech preparation phase of the Trier Social Stress Test (TSST) from the post-drug baseline; third, the change in average RSA that occurred across the 15-min of the TSST (speech + math tasks) from the post-drug baseline; fourth and finally, the change in average RSA that occurred across 7-min in a post-stressor recovery period as compared to the post-drug baseline. (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 2-min before the stressor; 15-min during stressor, 7-min recovery post-stressor
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Post-drug from pre-drug baseline | TSST-prep from post-drug baseline | TSST from post-drug baseline | Post-stress recovery from post-drug baseline | |
| Placebo | .27 | -.43 | -.87 | -.26 |
| Propanolol Hydrochloride | .11 | .36 | -.06 | .36 |
Concentration of alpha amylase in saliva quantified quantified by enzyme kinetic method. Two different change scores were calculated: first, the pre-drug to post-drug baseline change and, second, the 15-min post-stressor change from post-drug baseline. (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 15-min post-stressor
| Intervention | picograms / mL (Mean) | |
|---|---|---|
| Post-drug from pre-drug baseline | 15-min post-stress from post-drug baseline | |
| Placebo | -6.36 | 6.73 |
| Propanolol Hydrochloride | -7.50 | -15.68 |
Concentration of cortisol in saliva quantified quantified by chemiluminescence immunoassay with high sensitivity. Three different change scores were calculated from pre-drug to post-drug baselines, 15-min post-stressor from post-drug baseline, and 30-min post-stressor from post-drug baseline. (NCT02972554)
Timeframe: Pre-drug baseline; 60-min post-drug administration baseline before stressor; 15-min post-stressor; 30-min post-stressor
| Intervention | nanomole/L (Mean) | ||
|---|---|---|---|
| Post-drug from pre-drug baseline | 15-min post-stress from post-drug baseline | 30-min post-stress from post-drug baseline | |
| Placebo | -3.76 | 4.02 | 1.86 |
| Propanolol Hydrochloride | -6.42 | 5.61 | 2.1 |
1 review available for corticosterone and Fever
| Article | Year |
|---|---|
Clinical course of viral hepatitis.
Topics: Adult; Age Factors; Bilirubin; Cardiovascular Diseases; Child; Corticosterone; Diagnosis, Differenti | 1974 |
99 other studies available for corticosterone and Fever
| Article | Year |
|---|---|
Maternal protein malnutrition prolongs sickness behavior in male offspring.
Topics: Animals; Corticosterone; Endotoxemia; Female; Fever; Illness Behavior; Lactation; Lipopolysaccharide | 2020 |
Maternal care modulates the febrile response to lipopolysaccharide through differences in glucocorticoid receptor sensitivity in the rat.
Topics: Animals; Animals, Newborn; Behavior, Animal; Body Temperature; Corticosterone; Female; Fever; Glucoc | 2017 |
Involvement of interleukin-1 type 1 receptors in lipopolysaccharide-induced sickness responses.
Topics: Adrenocorticotropic Hormone; Animals; Anorexia; Brain; Corticosterone; Eating; Endothelial Cells; Fe | 2017 |
Acute psychosocial stress in mid-aged male rats causes hyperthermia, cognitive decline, and increased deep sleep power, but does not alter deep sleep duration.
Topics: Adrenocorticotropic Hormone; Aging; Animals; Body Temperature; Cognitive Dysfunction; Corticosterone | 2018 |
Prolonged sleep fragmentation of mice exacerbates febrile responses to lipopolysaccharide.
Topics: Animals; Behavior, Animal; Body Weight; Chronic Disease; Corticosterone; Data Interpretation, Statis | 2013 |
Glucocorticoids downregulate systemic nitric oxide synthesis and counteract overexpression of hepatic heme oxygenase-1 during endotoxin tolerance.
Topics: Adrenalectomy; Animals; Corticosterone; Dexamethasone; Disease Models, Animal; Down-Regulation; Endo | 2013 |
Calorie restriction dose-dependently abates lipopolysaccharide-induced fever, sickness behavior, and circulating interleukin-6 while increasing corticosterone.
Topics: Animals; Body Weight; Caloric Restriction; Corticosterone; Eating; Fever; Illness Behavior; Inflamma | 2014 |
Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice.
Topics: Administration, Oral; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Arachis; | 2014 |
Beneficial effects of a ketamine/atropine combination in soman-poisoned rats under a neutral thermal environment.
Topics: Animals; Anticonvulsants; Atropine; Body Temperature; Brain; Brain Injuries; Chemical Warfare Agents | 2015 |
Social factors modulate restraint stress induced hyperthermia in mice.
Topics: Animals; Body Temperature; Corticosterone; Fever; Mice; Mice, Inbred ICR; Restraint, Physical; Socia | 2015 |
Repeated Cold Stress Enhances the Acute Restraint Stress-Induced Hyperthermia in Mice.
Topics: Adipose Tissue, Brown; Adrenergic beta-3 Receptor Antagonists; Animals; Anti-Anxiety Agents; Cold Te | 2017 |
Effect of Physical Exercise on the Febrigenic Signaling is Modulated by Preoptic Hydrogen Sulfide Production.
Topics: Animals; Body Temperature Regulation; Corticosterone; Cystathionine beta-Synthase; Cystathionine gam | 2017 |
Implication of neuropeptide-Y Y2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice.
Topics: Analysis of Variance; Animals; Behavior, Animal; Corticosterone; Exploratory Behavior; Female; Fever | 2008 |
Oxytocin knockout mice: a model for studying stress-related and ingestive behaviours.
Topics: Animals; Body Temperature; Corticosterone; Crosses, Genetic; Environment; Feeding Behavior; Female; | 2008 |
Central nervous action of interleukin-1 mediates activation of limbic structures and behavioural depression in response to peripheral administration of bacterial lipopolysaccharide.
Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Brain; Corticosterone; Depression; Fever; | 2008 |
Bidirectional regulation of stress responses by galanin in mice: involvement of galanin receptor subtype 1.
Topics: Adrenocorticotropic Hormone; Animals; Brain; Corticosterone; Dose-Response Relationship, Drug; Fever | 2009 |
Chronic unpredictable stress augments +3,4-methylenedioxymethamphetamine-induced monoamine depletions: the role of corticosterone.
Topics: Animals; Body Temperature; Brain; Corpus Striatum; Corticosterone; Dopamine; Enzyme Inhibitors; Feve | 2009 |
REM sleep deprivation in rats results in inflammation and interleukin-17 elevation.
Topics: Animals; Biomarkers; Corticosterone; Fever; Homocysteine; Inflammation; Interleukin-17; Male; Rats; | 2009 |
Effects of prenatal immune activation on hippocampal neurogenesis in the rat.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroida | 2009 |
Serotonin 2 receptor modulation of hyperthermia, corticosterone, and hippocampal serotonin depletions following serial exposure to chronic stress and methamphetamine.
Topics: Amphetamine-Related Disorders; Animals; Behavior, Animal; Body Temperature Regulation; Central Nervo | 2010 |
Neonatal asphyxia under hyperthermic conditions alters HPA axis function in juvenile rats.
Topics: Animals; Animals, Newborn; Corticosterone; Fever; Hypothalamo-Hypophyseal System; Hypoxia; Pituitary | 2010 |
Low stress reactivity and neuroendocrine factors in the BTBR T+tf/J mouse model of autism.
Topics: Adaptation, Ocular; Animals; Autistic Disorder; Corticosterone; Corticotropin-Releasing Hormone; Dis | 2010 |
Vulnerability to chronic subordination stress-induced depression-like disorders in adult 129SvEv male mice.
Topics: Aggression; Animals; Anxiety; Chronic Disease; Corticosterone; Depression; Disease Models, Animal; D | 2011 |
Exogenous ghrelin attenuates endotoxin fever in rats.
Topics: Animals; Antipyretics; Body Temperature; Body Temperature Regulation; Corticosterone; Dinoprostone; | 2011 |
Metyrapone restores the febrile response to Escherichia coli LPS in pregnant rats.
Topics: Animals; Body Temperature; Body Temperature Regulation; Corticosterone; Enzyme Inhibitors; Escherich | 2011 |
Juvenile stress impairs body temperature regulation and augments anticipatory stress-induced hyperthermia responses in rats.
Topics: Adrenal Glands; Analysis of Variance; Animals; Animals, Newborn; Body Temperature; Body Temperature | 2011 |
Genetic, pharmacological and lesion analyses reveal a selective role for corticohippocampal GLUN2B in a novel repeated swim stress paradigm.
Topics: Analysis of Variance; Animals; Cerebral Cortex; Corticosterone; Dark Adaptation; Disease Models, Ani | 2011 |
Magnesium deficiency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Animals; Anxiety; Corticosterone; Corticotropin-R | 2012 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anxiety; Brain; Corticosterone; Depression | 2011 |
Prior laparotomy or corticosterone potentiates lipopolysaccharide-induced fever and sickness behaviors.
Topics: Animals; Behavior, Animal; Cells, Cultured; Corticosterone; Drug Synergism; Fever; Gram-Negative Bac | 2011 |
Effects of heat stress on endocrine functions & behaviour in the pre-pubertal rat.
Topics: Animals; Behavior, Animal; Corticosterone; Dehydroepiandrosterone Sulfate; Endocrine System; Fever; | 2012 |
Prenatal immune stress in rats dampens fever during adulthood.
Topics: Animals; Body Temperature; Corticosterone; Cyclooxygenase 2; Dose-Response Relationship, Drug; Endot | 2012 |
Involvement of glucocorticoid receptor on hyperpyrexia induced by methamphetamine administration.
Topics: Adrenalectomy; Animals; Body Temperature; Central Nervous System Stimulants; Corticosterone; Fever; | 2012 |
Intracerebral HIV-1 glycoprotein 120 produces sickness behavior and pituitary-adrenal activation in rats: role of prostaglandins.
Topics: Adrenocorticotropic Hormone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Cor | 2002 |
Circulating cytokines and endotoxin are not necessary for the activation of the sickness or corticosterone response produced by peripheral E. coli challenge.
Topics: Animals; Brain; Corticosterone; Escherichia coli Infections; Fever; Interleukin-1; Lipopolysaccharid | 2003 |
[UNCLASSIFIED FEVER BEFORE AND AFTER A DIAGNOSTIC EXPLORATORY LAPAROTOMY].
Topics: Arteritis; Corticosterone; Fever; Humans; Laparotomy | 1964 |
Chronic stress augments the long-term and acute effects of methamphetamine.
Topics: Amphetamine-Related Disorders; Animals; Body Weight; Chronic Disease; Corpus Striatum; Corticosteron | 2004 |
Stress-induced hyperthermia in the mouse: c-fos expression, corticosterone and temperature changes.
Topics: Animals; Body Temperature; Brain Chemistry; Corticosterone; Fever; Genes, fos; Immunohistochemistry; | 2004 |
Suppressed fever and hypersensitivity responses in chicks prenatally exposed to opiates.
Topics: Analysis of Variance; Animals; Basophils; Chick Embryo; Chickens; Corticosterone; Disease Models, An | 2004 |
A new function of the leptin receptor: mediation of the recovery from lipopolysaccharide-induced hypothermia.
Topics: Animals; Corticosterone; Cytokines; Encephalitis; Fever; Hypothermia; Kinetics; Lipopolysaccharides; | 2004 |
The febrile response to intraperitoneal lipopolysaccharide: strain and gender differences in rats.
Topics: Analysis of Variance; Animals; Body Temperature; Corticosterone; Dose-Response Relationship, Drug; E | 2005 |
Postpubertal sex differentiation of forebrain structures and functions depend on transforming growth factor-alpha.
Topics: Acoustic Stimulation; Age Factors; Aging; Animals; Animals, Newborn; Behavior, Animal; Brain; Catech | 2005 |
G-CSF, but not corticosterone, mediates circulating neutrophilia induced by febrile-range hyperthermia.
Topics: Animals; Corticosterone; Fever; Granulocyte Colony-Stimulating Factor; Male; Mice; Neutrophils | 2005 |
Protracted increases in core body temperature and interleukin-1 following acute administration of lipopolysaccharide: implications for the stress response.
Topics: Analysis of Variance; Animals; Body Temperature; Brain; Corticosterone; Dose-Response Relationship, | 2005 |
Interleukin-18 does not modulate the acute-phase response.
Topics: Acute-Phase Reaction; Animals; Body Temperature; Cholesterol; Corticosterone; Fever; Glucocorticoids | 2005 |
Hormonal, behavioral, and thermoregulatory responses to bacterial lipopolysaccharide in captive and free-living white-crowned sparrows (Zonotrichia leucophrys gambelii).
Topics: Acute-Phase Reaction; Aggression; Animals; Behavior, Animal; Body Temperature Regulation; Body Weigh | 2006 |
Early life immune challenge alters innate immune responses to lipopolysaccharide: implications for host defense as adults.
Topics: Adrenalectomy; Animals; Animals, Newborn; Corticosterone; Cytokines; Female; Fever; Hypothalamo-Hypo | 2005 |
Transiently enhanced LPS-induced fever following hyperthermic stress in rabbits.
Topics: Animals; Corticosterone; Fever; Interleukin-1; Lipopolysaccharides; Male; Rabbits; Recombinant Prote | 2005 |
Lipopolysaccharide-induced fever in Pekin ducks is mediated by prostaglandins and nitric oxide and modulated by adrenocortical hormones.
Topics: Animals; Anti-Inflammatory Agents; Corticosterone; Dexamethasone; Diclofenac; Ducks; Enzyme Inhibito | 2005 |
Fever suppression in near-term pregnant rats is dissociated from LPS-activated signaling pathways.
Topics: Animals; Corticosterone; Cytokines; Enzyme Activation; Female; Fever; Lipopolysaccharides; MAP Kinas | 2005 |
Early life host-bacteria relations and development: long-term individual differences in neuroimmune function following neonatal endotoxin challenge.
Topics: Age Factors; Aging; Analysis of Variance; Animals; Animals, Newborn; Corticosterone; Endotoxins; Fem | 2006 |
Neonatal programming of the rat neuroimmune response: stimulus specific changes elicited by bacterial and viral mimetics.
Topics: Age Factors; Animals; Animals, Newborn; Corticosterone; Fever; Hormone Antagonists; Lipopolysacchari | 2006 |
Lesions of the anteroventral third ventricle region exaggerate neuroendocrine and thermogenic but not behavioral responses to a novel environment.
Topics: Adrenocorticotropic Hormone; Animals; Behavior, Animal; Body Temperature; Colon; Corticosterone; Env | 2007 |
Chronobiological disturbances with hyperthermia and hypercortisolism induced by chronic mild stress in rats.
Topics: Analysis of Variance; Animals; Body Temperature; Chronobiology Disorders; Circadian Rhythm; Corticos | 2006 |
Behavioral evaluation of mice deficient in GABA(B(1)) receptor isoforms in tests of unconditioned anxiety.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Behavior, Animal; Corticosterone; Disease Models, Ani | 2007 |
Gene x environment effects: stress and memory dysfunctions caused by stress and gonadal factor irregularities during puberty in control and TGF-alpha hypomorphic mice.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Corticosterone; Fear; Female; Fever; Linear | 2008 |
Adaptation in the corticosterone and hyperthermic responses to stress following repeated stressor exposure.
Topics: Adaptation, Physiological; Animals; Behavior, Animal; Confined Spaces; Corticosterone; Dominance-Sub | 2007 |
Social status modulates basal IL-1 concentrations in the hypothalamus of pair-housed rats and influences certain features of stress reactivity.
Topics: Acute Disease; Animals; Corticosterone; Electroshock; Feeding Behavior; Fever; Hypothalamus; Interle | 2008 |
Reduced anxiety-like and depression-related behavior in neuropeptide Y Y4 receptor knockout mice.
Topics: Animals; Anxiety; Behavior, Animal; Corticosterone; Depression; Exploratory Behavior; Female; Fever; | 2008 |
Lesions of the medial prefrontal cortex enhance the early phase of psychogenic fever to unexpected sucrose concentration reductions, promote recovery from negative contrast and enhance spontaneous recovery of sucrose-entrained anticipatory activity.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Animals; Behavior, Animal; Body Temperature; Body | 2008 |
[Effect of a febrile response on adrenal cortex reactivity].
Topics: 11-Hydroxycorticosteroids; Adrenal Cortex; Adrenocorticotropic Hormone; Animals; Corticosterone; Fev | 1980 |
Corticosterone has a permissive effect on expression of heme oxygenase-1 in CA1-CA3 neurons of hippocampus in thermal-stressed rats.
Topics: Amino Acid Oxidoreductases; Animals; Cerebellum; Corticosterone; Cyclic GMP; Fever; Glucocorticoids; | 1995 |
Central effects of glucocorticoid receptor antagonist RU-38486 on lipopolysaccharide and stress-induced fever.
Topics: Animals; Anterior Hypothalamic Nucleus; Body Temperature; Brain; Corticosterone; Fever; Injections, | 1994 |
Corticosterone modulates interleukin-evoked fever in the rat.
Topics: Adrenalectomy; Animals; Body Temperature; Corticosterone; Fever; Injections, Intraventricular; Inter | 1994 |
Impaired febrile responses of aging mice are mediated by endogenous lipocortin-1 (annexin-1).
Topics: Aging; Animals; Annexin A1; Body Temperature; Corticosterone; Dinoprostone; Female; Fever; Immune Se | 1993 |
Glucocorticoids alter fever and IL-6 responses to psychological stress and to lipopolysaccharide.
Topics: Adrenalectomy; Animals; Body Temperature; Corticosterone; Fever; Glucocorticoids; Injections, Intrav | 1993 |
Stress-induced hyperthermia in mice. Pharmacological and endocrinological aspects.
Topics: Adrenocorticotropic Hormone; Animals; Blood Glucose; Corticosterone; Diazepam; Fever; Hypnotics and | 1995 |
Neuroendocrine effects of diazepam and flesinoxan in the stress-induced hyperthermia test in mice.
Topics: Adrenocorticotropic Hormone; Animals; Blood Glucose; Body Temperature; Corticosterone; Diazepam; Fev | 1996 |
Subchronic glucocorticoid pretreatment reversibly attenuates IL-beta induced fever in rats; IL-6 mRNA is elevated while IL-1 alpha and IL-1 beta mRNAs are suppressed, in the CNS.
Topics: Analysis of Variance; Animals; Antigens, CD; Body Temperature; Corticosterone; DNA Primers; Drug Imp | 1996 |
The CNS site of glucocorticoid negative feedback during LPS- and psychological stress-induced fevers.
Topics: Adrenalectomy; Animals; Corticosterone; Denervation; Dentate Gyrus; Feedback; Fever; Glucocorticoids | 1996 |
Effects of fetal alcohol exposure on fever, sickness behavior, and pituitary-adrenal activation induced by interleukin-1 beta in young adult rats.
Topics: Adrenocorticotropic Hormone; Animals; Behavior, Animal; Body Temperature; Corticosterone; Feeding Be | 1996 |
Hyperresponsive febrile reactions to interleukin (IL) 1alpha and IL-1beta, and altered brain cytokine mRNA and serum cytokine levels, in IL-1beta-deficient mice.
Topics: Animals; Body Temperature; Brain; Circadian Rhythm; Corticosterone; Cytokines; Escherichia coli; Fev | 1997 |
Effect of heat stress on LPS-induced fever and tumor necrosis factor.
Topics: Animals; Body Temperature; Body Temperature Regulation; Body Weight; Corticosterone; Escherichia col | 1997 |
Endocrine effects of pregnancy and exposure to a simulated open field in rats.
Topics: Animals; Arginine Vasopressin; Body Temperature Regulation; Corticosterone; Female; Fever; Handling, | 1997 |
Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion.
Topics: Animals; Body Weight; Brain; Corticosterone; Fever; Glucocorticoids; Inflammation; Interleukin-1; Li | 1998 |
Systemic alpha-MSH suppresses LPS fever via central melanocortin receptors independently of its suppression of corticosterone and IL-6 release.
Topics: Adrenocorticotropic Hormone; alpha-MSH; Animals; Body Temperature; Cerebral Ventricles; Corticostero | 1998 |
Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats.
Topics: Adrenocorticotropic Hormone; Animals; Behavior, Animal; Body Temperature; Corticosterone; Fever; Hum | 1999 |
Late embryonic ritanserin exposure fails to alter normal responses to immune system stimulation in young chicks.
Topics: Adjuvants, Immunologic; Animals; Antipsychotic Agents; Chick Embryo; Chickens; Corticosterone; Fever | 1999 |
Fetal alcohol exposure attenuates interleukin-1beta-induced fever: neuroimmune mechanisms.
Topics: Adrenocorticotropic Hormone; Alcoholism; Animals; Body Temperature Regulation; Corticosterone; Dinop | 1999 |
The amount of free corticosterone is increased during lipopolysaccharide-induced fever.
Topics: Animals; Body Temperature; Corticosterone; Fever; Heart Rate; Lipopolysaccharides; Male; Rats; Rats, | 2000 |
Repeated lipopolysaccharide administration produces tolerance to anorexia and fever but not to inhibition of thirst in rat.
Topics: Animals; Anorexia; Corticosterone; Cytokines; Drug Tolerance; Fever; Lipopolysaccharides; Male; NG-N | 2000 |
Lipopolysaccharide transport from the peritoneal cavity to the blood: is it controlled by the vagus nerve?
Topics: Adrenocorticotropic Hormone; Animals; Ascitic Fluid; Corticosterone; Diaphragm; Dose-Response Relati | 2000 |
Staphylococcal enterotoxin B induces fever, brain c-Fos expression, and serum corticosterone in rats.
Topics: Animals; Body Temperature; Body Temperature Regulation; Corticosterone; Enterotoxins; Fever; Injecti | 2001 |
Stress-induced hyperthermia in the 5-HT(1A) receptor knockout mouse is normal.
Topics: Animals; Corticosterone; Diazepam; Fever; GABA Modulators; Male; Mice; Mice, Knockout; Multivariate | 2001 |
Evaporative cooling of ventral regions of the skin in heat-stressed laying hens.
Topics: Animals; Body Temperature Regulation; Chickens; Corticosterone; Environment, Controlled; Estradiol; | 2001 |
Embryonic "binge" cocaine exposure alters neural-immune and neural-endocrine interactions in young chickens: involvement of serotonin(2) receptors.
Topics: Animals; Basophils; Chick Embryo; Chickens; Cocaine; Corticosterone; Dopamine Uptake Inhibitors; Fev | 2001 |
[Studies of plasma corticosterone in rats under various stress conditions].
Topics: Adrenal Cortex; Adrenal Glands; Animals; Corticosterone; Emotions; Fever; Fractures, Bone; Hypoglyce | 1975 |
Effects of corticoids on experimentally induced depression.
Topics: Adrenal Cortex Hormones; Animals; Antidepressive Agents; Body Temperature; Corticosterone; Fever; Hy | 1975 |
Endotoxin-induced fever is modulated by endogenous glucocorticoids in rats.
Topics: Adrenalectomy; Animals; Body Temperature; Corticosterone; Desoxycorticosterone; Dexamethasone; Endot | 1992 |
Selective depletion of macrophages prevents pituitary-adrenal activation in response to subpyrogenic, but not to pyrogenic, doses of bacterial endotoxin in rats.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Animals; Cell Count; Clodronic Acid; Corticosterone; Es | 1991 |
The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat.
Topics: Acute-Phase Proteins; Acute-Phase Reaction; Adrenergic beta-Antagonists; Animals; Corticosterone; Di | 1990 |
Fever and acute phase reactants in the rat.
Topics: Acute-Phase Proteins; Acute-Phase Reaction; Adrenalectomy; Animals; Atenolol; Autonomic Nerve Block; | 1988 |
Alpha-melanocyte-stimulating hormone exhibits target cell selectivity in its capacity to affect interleukin 1-inducible responses in vivo and in vitro.
Topics: alpha-MSH; Animals; Corticosterone; Dermatitis, Contact; Dinoprostone; Fever; Interleukin-1; Lymphoc | 1987 |
Acute febrile neutrophilic dermatosis (Sweet's syndrome) and the related conditions of "bowel bypass" syndrome and bullous pyoderma gangrenosum.
Topics: Acute Disease; Anti-Bacterial Agents; Arthritis; Colchicine; Corticosterone; Diagnosis, Differential | 1985 |
The effect of hyperthermia on the secretion of catecholamines, corticosterone and antidiuretic hormone and on the fibrinolytic activity of the plasma.
Topics: Adrenal Glands; Animals; Catecholamines; Corticosterone; Fever; Fibrinolysis; Male; Pituitary Gland, | 1974 |
Attempted transmission of the Ondiri disease (Bovine Petechial Fever) agent to laboratory rodents.
Topics: Animals; Animals, Laboratory; Bacteria; Blood; Cattle; Cattle Diseases; Corticosterone; Cricetinae; | 1973 |
Serious sequelae of general anesthesia.
Topics: Adult; Aged; Anesthesia, General; Chemical and Drug Induced Liver Injury; Circumcision, Male; Cortic | 1972 |
Participation of catecholamines and glucocorticoids in metabolic changes during endotoxin fever in rabbits.
Topics: Animals; Blood Glucose; Corticosterone; Endotoxins; Ergotamine; Fever; Glucose Tolerance Test; Injec | 1967 |
Stimulation of adrenal glucocorticoid secretion in man by raising the body temperature.
Topics: 17-Hydroxycorticosteroids; Adrenal Glands; Body Temperature; Corticosterone; Fever; Glucocorticoids; | 1969 |